Large-cap and small- to medium-cap biopharmaceutical companies in BofA Securities' coverage are not expected to be meaningfully impacted by the newly released pharma tariffs, analysts said in a Thursday note to clients.

Analysts said their top picks in large-cap pharmaceuticals are Bristol-Myers Squibb (BMY) and Merck (MRK). For small- to medium-cap biopharma stocks, they are Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS).

Ahead of the Q1 earnings season, BofA said investor focus for Johnson & Johnson (JNJ) is on the company's pending litigation regarding its talcum powder.

For Merck, the focus is on Keytruda diversification efforts and for Bristol-Myers Squibb, analysts are on the lookout for updates on its pipeline and mergers and acquisitions.

Regarding Eli Lilly, investors are focused on updates on the launch of its orforglipron weight loss drug and the performance of tirzepatide.

For AbbVie (ABBV), the key focus will be on management's commentary regarding the outlook for the Skyrizi psoriasis drug, BofA said.

Analysts changed the price targets for several companies under their pharma coverage.

Alkermes' price target was raised to $36 from $34, Bristol-Myers Squibb's to $68 from $67, Ionis' to $100 from $111, Pfizer's (PFE) to $27 from $26 and Teva Pharmaceutical Industries' (TEVA) to $38 from $42.

Price: 59.02, Change: -0.19, Percent Change: -0.31